

# Frontiers in Clinical Drug Research (Anti-Cancer Agents)



Editor:  
**Atta-ur-Rahman, *FRS***

**Bentham Books**

**Frontiers in Clinical Drug  
Research - Anti-Cancer Agents**  
*(Volume 7)*

Edited By

**Atta-ur-Rahman, *FRS***

*Kings College,  
University of Cambridge,  
Cambridge,  
UK*

## **Frontiers in Clinical Drug Research – Anti-Cancer Agents**

*Volume # 7*

Editor: Prof. Atta-ur-Rahman, *FRS*

ISSN (Online): 4437/2: 25

ISSN (Print): 4673/; ; 27

ISBN (Online): 978-1-68108-775-7

ISBN (Print): 978-1-68108-776-4

ISBN (Paperback): 978-1-68108-777-1

©2021, Bentham eBooks imprint.

Published by Bentham Science Publishers – Sharjah, UAE. All Rights Reserved.

## **BENTHAM SCIENCE PUBLISHERS LTD.**

### **End User License Agreement (for non-institutional, personal use)**

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [permission@benthamscience.net](mailto:permission@benthamscience.net).

### **Usage Rules:**

1. All rights reserved: The Work is 1. the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

### ***Disclaimer:***

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

### ***Limitation of Liability:***

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

### **General:**

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of the U.A.E. as applied in the Emirate of Dubai. Each party agrees that the courts of the Emirate of Dubai shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

**Bentham Science Publishers Ltd.**

Executive Suite Y - 2

PO Box 7917, Saif Zone

Sharjah, U.A.E.

Email: [subscriptions@benthamscience.net](mailto:subscriptions@benthamscience.net)



## CONTENTS

<b>PREFACE</b> .....	ii
<b>LIST OF CONTRIBUTORS</b> .....	iii
<b>CHAPTER 1 ESSENTIAL OILS AND MONOTERPENES AS POTENTIAL ANTI-CANCER AGENTS</b> .....	1
<i>Julia Pérez-Ramos, Nimsi Campos-Xolalpa, Roberto Serrano, Cuauhtemoc Pérez and Salud Pérez</i>	
<b>INTRODUCTION</b> .....	2
<b>DISCUSSION</b> .....	25
<b>CANCER CELL LINE</b> .....	26
<b>ABBREVIATIONS</b> .....	26
<b>CONSENT FOR PUBLICATION</b> .....	27
<b>CONFLICT OF INTEREST</b> .....	27
<b>ACKNOWLEDGEMENTS</b> .....	27
<b>REFERENCES</b> .....	27
<b>CHAPTER 2 A GLANCE AT DRUG DELIVERY SYSTEMS AND EMERGING IMMUNOTHERAPEUTIC STRATEGIES FOR THE TREATMENT OF GLIOBLASTOMA</b> ...	37
<i>Greta Varchi, Marzia Bruna Gariboldi and Claudia Ferroni</i>	
<b>INTRODUCTION</b> .....	38
<b>GLIOBLASTOMA STANDARD TREATMENT</b> .....	42
<b>IMMUNOTHERAPY IN GBM</b> .....	43
Immunomodulator Therapy .....	49
Passive Immunotherapy: Current State of Immune Checkpoint Inhibitors and Adoptive Therapy .....	51
<i>Immune Checkpoint Inhibitors (ICIs)</i> .....	51
<i>Adoptive Cell Therapy</i> .....	53
Current Vaccine Trials in GBM .....	54
<i>Dendritic Cell Vaccine</i> .....	54
<i>Peptide Vaccine</i> .....	55
<i>Heat Shock Protein-based Vaccine</i> .....	56
Combination Strategies .....	56
<i>Checkpoint Inhibitors Combination Therapy</i> .....	56
<i>Different Combination Strategies Targeting Other Immunotherapeutic Pathways</i> .....	59
<b>DRUG DELIVERY-BASED APPROACH</b> .....	59
Pre-clinical Studies on Brain-targeted Nanocarriers .....	62
Clinical Studies on Brain-targeted Nanocarriers .....	66
<b>CONCLUSION AND FUTURE ADVANCES</b> .....	68
<b>CONSENT FOR PUBLICATION</b> .....	69
<b>CONFLICT OF INTEREST</b> .....	69
<b>ACKNOWLEDGEMENTS</b> .....	69
<b>REFERENCES</b> .....	69
<b>CHAPTER 3 CTDNA IN SOLID TUMORS: ROLE IN DIAGNOSIS, PROGNOSIS AND TREATMENT</b> .....	82
<i>Sevgi Akaydin, Ece Miser Salihoğlu and Dolunay Merve Fakioğlu</i>	
<b>INTRODUCTION</b> .....	82
<b>BREAST CANCER</b> .....	86
ctDNA as Diagnostic Biomarker of Breast Cancer .....	86
ctDNA as Prognostic Biomarker of Breast Cancer .....	88

ctDNA in the Targeted Therapy of Breast Cancer .....	89
<b>NON-SMALL CELL LUNG CANCER</b> .....	91
ctDNA as Diagnostic Biomarker of Non-Small Cell Lung Cancer .....	92
ctDNA as Prognostic Biomarker of Non-Small Cell Lung Cancer .....	92
ctDNA in the Targeted Therapy of Non-Small Cell Lung Cancer .....	94
<b>COLORECTAL CANCER</b> .....	96
Epigenetic Markers as a Diagnostic Biomarker in Colorectal Cancer .....	97
ctDNA as a Diagnostic Biomarker in Colorectal Cancer .....	97
ctDNA as Prognostic Biomarker in Colorectal Cancer .....	99
Predictive ctDNA Markers in Colorectal Cancer .....	99
<b>PROSTATE CANCER</b> .....	103
ctDNA as Diagnostic Biomarker in Prostate Cancer .....	103
ctDNA as Prognostic Biomarker in Prostate Cancer .....	104
Predictive ctDNA Markers in Prostate Cancer .....	105
<b>OTHER TUMORS</b> .....	106
Gastrointestinal Stromal Tumors .....	106
Head and Neck Cancer Squamous Cell Carcinoma .....	108
Ovarian Cancer .....	111
<b>CONCLUSION</b> .....	113
<b>CONSENT FOR PUBLICATION</b> .....	114
<b>CONFLICT OF INTEREST</b> .....	114
<b>ACKNOWLEDGEMENTS</b> .....	114
<b>REFERENCES</b> .....	114
<b>CHAPTER 4 PITAVASTATIN AND CANCER: CURRENT AND FUTURE PROSPECTS</b> .....	132
<i>Saeb Aliwaini</i>	
<b>INTRODUCTION</b> .....	132
<b>PITAVASTATIN: THE CHEMICAL COMPOUND</b> .....	134
<b>ANTI-CANCER PROPERTIES OF PITAVASTATIN</b> .....	135
Antitumor Effects of Pitavastatin <i>In Vitro</i> .....	135
<i>Anti-proliferative Effect of Pitavastatin</i> .....	136
<i>Induction of Cell Cycle Arrest</i> .....	137
<i>Apoptosis Activation</i> .....	138
<i>Activation of Autophagy</i> .....	139
<i>Anti-migration Effect</i> .....	141
<i>Anti-inflammatory Effect</i> .....	141
Antitumor Effects of Pitavastatin <i>In Vivo</i> .....	142
<i>Chemical Carcinogenesis Studies</i> .....	143
<i>Tumor Xenograft Studies</i> .....	144
<b>PITAVASTATIN TARGETS CELLULAR PATHWAYS</b> .....	145
<b>LIMITATIONS</b> .....	146
<b>CONCLUSION AND FUTURE PERSPECTIVE</b> .....	147
<b>CONSENT FOR PUBLICATION</b> .....	148
<b>CONFLICT OF INTEREST</b> .....	148
<b>ACKNOWLEDGEMENTS</b> .....	148
<b>REFERENCES</b> .....	148
<b>CHAPTER 5 CHOLESTEROL: A POTENTIAL TARGET FOR INTERVENTION IN ANTI-CANCER THERAPY</b> .....	154
<i>Nimai Chand Chandra, Amar Preet Kaur, Ayantika Talukdar, Nimisha Saxena and Shrimanjanath Sankanagoudar</i>	
<b>INTRODUCTION</b> .....	155

<b>POLYCYCLIC HYDROCARBONS</b> .....	157
Potential Carcinogenic Effect .....	157
Polycyclic Cholesterol: A Perspective on Cell Proliferation and Carcinogenicity .....	157
<b>TRANSMEMBRANE CHOLESTEROL TRANSPORTERS</b> .....	159
Plasma Membrane Transporter: LDLR .....	159
Mitochondrial Membrane Transporter: StAR and PBR .....	159
Nuclear Membrane Transporter: PBR .....	160
<b>INTER-CORRELATION BETWEEN CHOLESTEROL TRANSPORTERS AND CELL PROLIFERATION</b> .....	162
<b>INTRACELLULAR CHOLESTEROL, CELL CYCLE ACTIVITY AND CELL PROLIFERATION</b> .....	163
<b>CHOLESTEROL: A STEER TO CELL CYCLE ACTIVITY AND CELL PROLIFERATION</b> .....	163
<b>CHOLESTEROL HOMEOSTASIS IN CANCER TUMOUR CELLS</b> .....	167
Cholesterol Homeostasis in Leukemia .....	168
Cholesterol Homeostasis in Prostate Carcinoma .....	169
Cholesterol Homeostasis in Breast Carcinoma .....	170
<b>REPROGRAMMED CHOLESTEROL METABOLISM IN CANCER CELLS</b> .....	171
<b>IMMUNE CELL SUPPRESSION BY CARCINOGEN AND CARCINOMA</b> .....	173
Does Carcinogen Target Cholesterol to Abrogate Immune Cells? .....	174
Effect of Carcinogen on T-Cell Immunity and the Role of Cholesterol .....	175
Effect of Carcinogen on B-cell Immunity and the Role of Cholesterol .....	176
<b>BIPHASIC ROLE OF CHOLESTEROL IN PROMOTING TUMOR CELL PROLIFERATION AND TUMOR DEFENSIVE IMMUNE CELL DEATH</b> .....	177
<b>ANTI-CANCER ANTI-CHOLESTEROL TARGET</b> .....	179
<b>ANTI-CANCER DRUG TARGETS: PREVENTION AGAINST INIMICAL DOUBLE- EDGED REPROGRAMMED CHOLESTEROL HOMEOSTASIS</b> .....	180
<b>SUMMARY AND CONCLUSION</b> .....	184
<b>CONSENT FOR PUBLICATION</b> .....	185
<b>CONFLICT OF INTEREST</b> .....	185
<b>ACKNOWLEDGEMENTS</b> .....	185
<b>REFERENCES</b> .....	185
<b>SUBJECT INDEX</b> .....	202



## PREFACE

Frontiers in Clinical Drug Research - Anti-Cancer Agents presents recent developments of various therapeutic approaches against different types of cancer. The book is a valuable resource for pharmaceutical scientists, postgraduate students, and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research.

The five chapters in this volume are written by eminent authorities in the field. Chapter 1 presents the latest research progress in the use of essential oils and monoterpenes as anti-cancer agents. Chapter 2 gives an overview of current innovative approaches to glioblastoma, focusing on the therapeutic benefits of immunotherapeutic agents and drug delivery systems. Chapter 3 summarizes the roles of ctDNA in clinical practice for diagnosis, treatment choices and responses to therapy in various solid cancers. Chapter 4 focuses on the anti-cancer effects of pitavastatin, including its mechanism of action as well as the potential adverse reactions linked to its clinical use. Chapter 5 discusses the biphasic role of cholesterol, in and around the cancer tumor, as a model target for anti-cancer therapeutic management.

I hope that the readers will find these reviews valuable and thought-provoking so that they may trigger further research in the quest for new and novel therapies against cancers.

I am grateful for the timely efforts made by the editorial personnel, especially Mr. Mahmood Alam (Director Publications) and Mrs. Salma Sarfaraz (Senior Manager Publications) at Bentham Science Publishers.

**Atta-ur-Rahman, *FRS***  
Kings College  
University of Cambridge  
Cambridge  
UK

## List of Contributors

<b>Amar Preet Kaur</b>	Department of Biochemistry, All India Institute of Medical Sciences, Gorakhpur, India
<b>Ayantika Talukdar</b>	Division of Genetics and Development, University Health Network, Toronto, Canada
<b>Claudia Ferroni</b>	Department of Biotechnology and Life Sciences (DBSV), University of Insubria, Varese, Italy
<b>Cuauhtemoc Pérez</b>	Departamento de Sistemas Biológicos, Universidad Autónoma Metropolitana-Xochimilco, Calzada del Hueso 1100, Col. Villa Quietud Ciudad de México, México
<b>Dolunay Merve Fakioglu</b>	Department of Biochemistry, Gazi University Faculty of Pharmacy, Ankara, Turkey
<b>Ece Miser Salihoglu</b>	Department of Biochemistry, Gazi University Faculty of Pharmacy, Ankara, Turkey
<b>Greta Varchi</b>	Italian National Research Council, Institute of Organic Synthesis and Photoreactivity (ISOF), Bologna, Italy
<b>Julia Pérez-Ramos</b>	Departamento de Sistemas Biológicos, Universidad Autónoma Metropolitana-Xochimilco, Calzada del Hueso 1100, Col. Villa Quietud Ciudad de México, México
<b>Marzia Bruna Gariboldi</b>	Department of Biotechnology and Life Sciences (DBSV), University of Insubria, Varese, Italy
<b>Nimsi Campos-Xolalpa</b>	Departamento de Sistemas Biológicos, Universidad Autónoma Metropolitana-Xochimilco, Calzada del Hueso 1100, Col. Villa Quietud Ciudad de México, México
<b>Nimisha Saxena</b>	Department of Biochemistry, KDMCH & Research Center, Akbarpur, Mathura, India
<b>Nimai Chand Chandra</b>	Department of Biochemistry, All India Institute of Medical Sciences, Patna, India
<b>Roberto Serrano</b>	Departamento de Sistemas Biológicos, Universidad Autónoma Metropolitana-Xochimilco, Calzada del Hueso 1100, Col. Villa Quietud Ciudad de México, México
<b>Salud Pérez</b>	Departamento de Sistemas Biológicos, Universidad Autónoma Metropolitana-Xochimilco, Calzada del Hueso 1100, Col. Villa Quietud Ciudad de México, México
<b>Shrimanjanath Sankanagoudar</b>	Department of Biochemistry, All India Institute of Medical Sciences, Basni, Jodhpur, Rajasthan, India
<b>Saeb Aliwaini</b>	Department of Biological Sciences and Biotechnology, Faculty of Sciences, Islamic University of Gaza, Rimal Street, Gaza 108, Palestine
<b>Sevgi Akaydin</b>	Department of Biochemistry, Gazi University Faculty of Pharmacy, Ankara, Turkey

---

**CHAPTER 1**

---

**Essential Oils and Monoterpenes as Potential Anti-Cancer Agents****Julia Pérez-Ramos<sup>1</sup>, Nimsi Campos-Xolalpa<sup>1</sup>, Roberto Serrano<sup>1</sup>, Cuauhtemoc Pérez<sup>1</sup> and Salud Pérez<sup>1,\*</sup>**<sup>1</sup> *Universidad Autónoma Metropolitana-Xochimilco, Departamento de Sistemas Biológicos, Calzada del Hueso 1100, Col. Villa Quietud Ciudad de México, México 04960*

**Abstract:** Cancer is a complex disease, and some projections indicate that in 2030, cancer mortality will reach approximately 11.4 million deaths worldwide. One treatment for cancer is chemotherapy. However, cancer cells could present resistance to the therapeutic compounds, and these compounds also have adverse effects. New drugs with anticancer activity have been successfully found in plants. Essential oils (EOs) are a mixture of over 100 volatile organic compounds abundant in aromatic plants. EOs are mainly composed of compounds of low molecular weight, such as monoterpenes, sesquiterpenes, and phenolic compounds. The chemical composition of EOs depends mainly on the plant species, place of origin, and climatic conditions. Generally, the EO density at room temperature is lower than that of water. They are brown, yellow, or colorless, and they have a perceptible aroma. EOs have been used throughout history in different areas, such as in foods, cosmetics, cleaning supplies, and traditional medicine for the treatment of certain health problems. Monoterpenes, built from two isoprene molecules, are hydrocarbon terpenes and oxygenated compounds (terpenoids), such as alcohols, aldehydes, ketones, acids, and esters. Monoterpenes are one of the main chemical constituents of EOs that have appeared in a large number of studies, and their anticancer efficacy has been documented between 2015-2020. This review presents the latest research progress in the use of EOs and monoterpenes as anticancer agents. The 115 EOs and 26 monoterpenes obtained from 36 different plant families included in this review show that Asteraceae and Lamiaceae have been the most studied families during this period.

**Keywords:** Antitumoral activity, Cytotoxic activity, Cancer, Cell lines, Essential oils, Monoterpenes.

---

\* **Corresponding author Salud Pérez:** Department of Sistemas Biológicos, University Autónoma Metropolitana-Xochimilco, Calzada del Hueso 1100, Col. Villa, Ciudad de México, México. E-mail:msperez@correo.xoc.uam.mx

Atta-ur-Rahman (Ed.)

All rights reserved-© 2021 Bentham Science Publishers

## INTRODUCTION

Cancer is a disease with one of the highest rates of death worldwide. In 2018, 9.6 million deaths were attributed to cancer. Cancer is a disease with significant mortality and morbidity in all regions of the world. The mortality and incidence of cancer are rapidly increasing worldwide. The increase is associated with age and growing population and changes in the prevalence of the main risk factors for cancer [1].

The types of cancer with the highest number of deaths worldwide are lung, liver, gastric, colorectal, and breast cancer. In men, the most frequent type of cancer (the main cause of death) is lung cancer, followed by prostate, colorectal, liver, and stomach cancer. Additionally, in women, breast cancer is the most frequently diagnosed and is the main cause of death, followed by lung and colorectal cancer. Cervical cancer is fourth in incidence and mortality. However, the type of cancer with the highest diagnosis rate and the highest death rate varies between countries depending on economic development, social factors, and the lifestyle of the populations [2].

The main causes of cancer have been determined to be physical (ultraviolet radiation), chemical (asbestos, tobacco smoke, aflatoxins, and arsenic), and biological (viruses, bacteria, and parasites). Cancer development can also be caused by the hereditary genetic load of the body [3].

Cancer is characterized by the accelerated and uncontrolled growth of cells. Cancer defines malignant neoplasms characterized by metastatic growth [4]. It can occur in almost any organ or tissue in relation to a variety of etiological factors, such as genomic instability and environmental stress [4]. During the development of cancer, a multistep process is present, during which genetic alterations confer specific types of growth benefits; these alterations, therefore, drive the progressive transformation from normal cells to malignant cancer cells. Alterations in malignant cell growth are characterized by several key changes. Cells tend to alter their division cycle, presenting the following characteristics: sustaining proliferative signaling, evading growth suppressors, resisting cell death producing angiogenesis, activating invasion to other organs, metastasis, and enabling replicative immortality [5]. Cancer cells can generate a tumor, an irregular mass of tissue, which may or may not be solid, and can be differentiated into malignant or benign forms. Malignant forms can grow rapidly, invade and metastasize, and potentially cause death. There are several treatments of cancer, such as radiation therapy, surgery, hormone therapy, immunotherapy, and chemotherapy. These treatments can be used individually or concomitantly, depending on the stage of advancement of cancer [1]. Chemotherapy is a

treatment based on the use of drugs with cytotoxic activity, and in some cases, it can be applied before surgery in order to reduce the size of the tumor. Cytotoxic compounds can induce death in cancer cells, and the type of death that occurs is apoptosis [6]. Cell death by apoptosis aids in tissue homeostasis. This process is carried out by mitochondrial permeabilization and caspase activation. Chromatin condensation and DNA fragmentation are characteristics of apoptotic cells, which are ultimately eliminated by phagocytes. The dysregulation of apoptosis can contribute to pathologies such as cancer, autoimmune or neurodegenerative diseases [7].

More than 80% of chemotherapy drugs have been obtained from plants [8]. These drugs have shown activity against cancer. However, they also produce adverse effects, so alternatives are currently being sought for this disease. EOs and their different constituents have been a new source of cytotoxic and antitumor compounds. Currently, different *in vivo* and *in vitro* studies have been performed.

Many cultures have used EOs in religious practices, dating back to as early as 6000 BC. Later, ancient Egyptians used cypress, spikenard, and lotus oils in rituals and placed amphoras containing fragrant oils in the tombs for the voyage to the afterlife [9]. Additionally, they used EOs in medicine, perfumery, and cleansing. In Greece, visions of the oracles at Delphi came through inhalation of the smoke produced by *Laurus nobilis* [10]. The Greek and the Romans associated fragrances with their gods, but they also used EOs in baths and perfumery. The Persians made great contributions to the knowledge of aromatics and medicine. When the Crusaders returned to Europe, they brought perfumes, aromatics, and remedies unknown to Europeans before. Over the next few hundred years, the range of aromatic medicines became more popular, and the industry of EOs increased, providing oils for fragrance, flavor, and pharmaceutical purposes. In recent years, the therapeutic use of EOs has increased [11].

EOs are defined as highly concentrated aromatic oils of plant origin that are obtained from the leaves, flowers, barks, seeds, fruit peels, and rhizomes. EOs are a complex mixture of low molecular weight compounds, such as monoterpenes, sesquiterpenes, straight-chain aliphatic, aromatic, or heterocyclic compounds, and in some oils, allyl sulfides are found [12]. Many oils contain between a few dozen to 200 compounds. The chemical composition of EOs depends on many factors, such as the climate, season, geographical location, plant maturity, drying method, genetic variation, and stress during growth and storage. Thus, the variability in the EOs composition influences their properties [13, 14]. EOs are obtained by hydro or steam distillation [15], solvent extraction, supercritical fluid extraction [16], or cold pressing process [17].

## CHAPTER 2

# A Glance at Drug Delivery Systems and Emerging Immunotherapeutic Strategies for the Treatment of Glioblastoma

Greta Varchi<sup>1</sup>, Marzia Bruna Gariboldi<sup>2</sup> and Claudia Ferroni<sup>2,\*</sup>

<sup>1</sup> Italian National Research Council, Institute of Organic Synthesis and Photoreactivity (ISOF), via Piero Gobetti 101, 40129 Bologna, Italy

<sup>2</sup> Department of Biotechnology and Life Sciences (DBSV), University of Insubria, via J.H. Dunant 3, 21100 Varese, Italy

**Abstract:** Glioblastoma (GBM) represents the most common and aggressive primary brain tumor with a 5-years survival rate lower than 10%. GBM worldwide incidence is about two to three per 100000 adults per year, and the standard treatment encompasses surgical debulking with subsequent radiation therapy and concomitant chemotherapy.

Given its heterogeneity, its intracranial location and the onset of multidrug resistance mechanisms, new tailored approaches, such as immunotherapy and drug delivery systems, have recently gained increasing interest. In recent years, tumor microenvironment exploration has revealed that immune response evasion is one of the crucial GBM diagnostic hallmarks. Since this discovery, the possibility to reverse tumor-mediated immunosuppression has received increasing attention, changing the paradigm of cancer treatment from chemotherapy to immunotherapy. On the other hand, the blood-brain barrier (BBB) represents the main challenge in developing therapeutics for central nervous system (CNS) tumors; for instance, 100% of large molecules and 98% of small molecules fail to achieve sufficient therapeutic doses at the brain. To this purpose, nanotechnology-based drug delivery systems represent promising platforms to improve drug bioavailability, reduce side effects and allow the co-delivery of multiple drugs to the target cells.

This chapter gives an overview of current innovative approaches to GBM focusing on the therapeutic benefit of immunotherapeutic agents and drug delivery systems. In particular, we aim to provide a summary of the recent clinical trials using immunomodulator, immune checkpoint inhibitors (ICIs), *i.e.* monoclonal antibodies (mAbs) blocking cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death-1 (PD-1/PD-L1a), vaccination therapy. Although ICIs and vaccines have shown limited efficacy when used as monotherapy, promising results have been reported for their combination with immune adjuvants, such as chemo,

---

\* **Corresponding Author Claudia Ferroni:** Claudia Ferroni, Italian National Research Council, Institute of Organic Synthesis and Photoreactivity (ISOF), via Piero Gobetti 101, 40129 Bologna, Italy E-mail: claudia.ferroni@isof.cnr.it

radio- and photodynamic therapies, suggesting an emerging strategy for a more successful antitumoral immune response. With this chapter, we aim to provide an overview of the state-of-the-art and future perspective of GBM treatment, mainly addressed to pharmaceutical students and researchers in the field of clinical drug research.

**Keywords:** Blood-Brain Barrier (BBB), Blood-Brain Tumor Barrier (BBTB), Clinical trials, Combination approach, Drug Resistance, Glioblastoma, Immune Checkpoint Inhibitors (ICIs), Immunotherapy, Long-term Immune Memory, Nanocarriers, Nanomedicine, Vaccine.

## INTRODUCTION

Glioblastoma (GBM), accounting for 54% of all gliomas and 16% of all primary malignant tumors of central nervous system (CNS), is the most common and aggressive brain tumor in adults [1]. The median age for the development of GBM is 64 years, but it can occur at every age, including childhood; most GBM are primary or *de novo* tumors without a known precursor, characterized by poor prognosis and most common in older patients (Fig. 1) [2].

Despite advances in surgical techniques, radiation therapy, chemotherapy, and new therapies based on targeted agents and immune modulators, patients' survival remains low, with a 5-year survival rate lower than 10% [1, 3]. Several factors might influence GBM prognosis, such as the extent of surgical resection, tumor molecular classification, patients' age and Karnofsky Performance Status (KPS) at diagnosis. Specifically, lower age and higher KPS bestow more prolonged survival. Moreover, tumors greater than 5-6 cm at diagnosis, and those crossing the mid-line have been associated with negative outcome, whereas cerebrum and cerebellar tumors that are more accessible with surgery, lead to better prognosis [3, 4].

Aside from age, which is known to play a crucial role, and the exposure to ionizing radiations, responsible for a limited number of cases, GBM's risk factors are overall poorly established [5 - 7]. Only less than 1% of GBM is associated with hereditary cancer syndromes, such as Turcot syndrome, Li-Fraumeni syndrome, tuberous sclerosis and neurofibromatosis types 1 and 2 [8]. Environmental exposure, infections, trauma, smoking, cell phone use, and pollution do not seem to be involved in GBM development [9, 10].

The association between GBM incidence and specific genes, accounting for nearly 27% of familial risk [3], has been investigated by the Cancer Genome Atlas project (TCGA), which showed that most GBM present activation of three different pathways, namely retinoblastoma, tumor suppressor p53 and receptor

tyrosine kinase/Ras/phosphoinositide 3-kinase signaling pathway [3, 4, 11]. Importantly, future transcriptome-wide association investigations, together with molecular epidemiology studies, might unravel new targets for GBM treatment, predictors of side effects, and prognostic markers, contributing to better management of this disease.




Fig. (1). GBM general characteristics.

Based on histologic diagnosis, GBM is characterized by increased cell density, atypia, areas of necrosis, and robust angiogenesis [12, 13]. Furthermore, GBM has a strong brain tropism and only rarely disseminates into organs, probably due to the metabolic adaptation and immunologic peculiarities of the brain microenvironment [14 - 16].

GBM is classified as primary or *de novo* tumor without a known clinical precursor, or secondary GBM, which is most often considered as the progression/transformation of lower-grade gliomas. In 2016, the WHO revised brain tumors classification incorporating tumor genetic alterations to the classic histological ones [12]. Therefore, circumscribed gliomas (grade I) were classified as mostly benign and curable by complete resection, while gliomas from grade II to IV result more diffuse and infiltrating, thus very rarely cured by resection (Fig. 2) [17].



## ctDNA in Solid Tumors: Role in Diagnosis, Prognosis and Treatment

Sevgi Akaydin<sup>1,\*</sup>, Ece Miser Salihoğlu<sup>1</sup> and Dolunay Merve Fakioglu<sup>1</sup>

<sup>1</sup> Gazi University Faculty of Pharmacy, Department of Biochemistry, Ankara, Turkey

**Abstract:** Solid tumors have long been known constantly to shed many biomolecules such as DNA, RNA and proteins into the blood and other body fluids. These biomolecules can circulate in the blood free of cells or by binding to proteins or lipids. Circulating tumor DNA (ctDNA) is tumor-derived cell-free DNA (cfDNA) and is often confused with non-tumor derived cfDNA. Recent advances in laboratory techniques enable better capture and analysis of trace amounts of circulating materials. Liquid biopsy is a minimally invasive method and allows analyses of circulating tumor cells released from peripheral tumors and/or metastatic tumors and nucleic acids in the cell-free circulation, in particular ctDNA, microRNA and extracellular RNA. The fact that ctDNA completely reflects the tumor genome has made it a powerful clinical and research tool in liquid biopsy, and a number of studies have been conducted on the diagnostic, predictive and / or prognostic use of ctDNA in cancer over the last few years. There are studies confirming the clinical validity of ctDNA for detecting tumor heterogeneity and resistance mutation, identifying candidates for targeted therapies, disease monitoring and therapeutic response assessment, early detection of recurrence, monitoring tumor burden, and risk classification. In this chapter, we have summarized the roles of ctDNA in clinical practice for diagnosis, treatment choices and responses to therapy in various solid cancers.

**Keywords:** Breast cancer, Cell-free DNA, Circulating tumor cells, Circulating tumor DNA, Colorectal cancer, Head and neck cancer squamous cell carcinoma, Liquid biopsy, Non-small cell lung cancer, Prostate cancer gastrointestinal stromal tumor, Solid tumors.

### INTRODUCTION

Cancer diagnosis and treatment are based on the phenotypic or genotypic features of the cancer cells and potential treatment is possible with early diagnosis. Solid biopsy, an integral part of the tumor, is often needed for diagnosis, staging, and monitoring of disease progression and establishing effective treatment for cancer

\* Corresponding author Sevgi Akaydin: Gazi University Faculty of Pharmacy, Department of Biochemistry, Ankara, Turkey; Tel: +90(535) 277 11 06; E-mail: sevgiy@gazi.edu.tr

patients, but has several drawbacks, which are bleeding, nerve injury or the risk of spreading the disease. In heterogeneous tumors (*e.g.*, breast tumors), tissue biopsy may not represent the entire tumor, and for tumors in hard-to-reach regions (*e.g.*, such as lung, breast and pancreatic cancers), obtaining a solid biopsy can be painful for the patient and may cause death. Therefore, obtaining cancer cells using non-invasive methods with a low risk of complications is advantageous for both the patient and the physician. When the metastasis process is effectively interfered with, effective cancer treatment can be achieved.

The main characteristic of malign tumors is their ability to metastasize. The clinical appearance of metastasis in distant organs is the final stage of cancer and is the cause of most cancer-related deaths [1]. The basis of metastasis biology is that the tumor cells show a tendency to transfer from the primary region into distant organs where the cells can remain asleep until they begin to regrow [2]. These cells are called circulating tumor cells (CTCs). In cancer patients, blood may contain other analytes besides CTCs, such as circulating tumor DNA (ctDNA), which is released from tumor cells and could be single or double-stranded and cell-free DNA (cfDNA) which includes DNA fragments from normal cells and extracellular vesicles (exosomes) [3].

Considering the generally accepted cancer models, the spread of cells from the primary cancer region into the circulation can be considered as an advanced stage, but it has been shown that cancer starts releasing neoplastic cells into the bloodstream before they reach the metastatic stage, and even earlier [4, 5]. However, cancer patients have more fragmentation of DNA than healthy individuals [6].

In 1869, pathologist Thomas Ashworth noticed CTCs in the blood of a metastatic cancer patient and turned them into what is now called liquid biopsy (Table 1) [7 - 20].


**Table 1. Landmarks in the detection of liquid biopsy development.**

1948	1977	1989	1994	1996	1997	2005	2012-2013	2014	2017	2019-2020
cfDNA was first reported in human	Leon <i>et al.</i> found increased cfDNA	Stroun <i>et al.</i> first reported the appearance of	Sorenson <i>et al.</i> were detected a mutated RAS gene fragment	Nawroz <i>et al.</i> were first reported the detection of microsatellite	Lo <i>et al.</i> were reported the discovery of the cell-free	Diehl <i>et al.</i> were studied detection and	Attention to the detection and follow-up	First clinical validation of the detection	ctDNA analysis kits started to be	ctDNA analysis could be a potential

(Table 1) *cont....*

1948	1977	1989	1994	1996	1997	2005	2012-2013	2014	2017	2019-2020
plasma by Mandel and Metais [7].	levels in the serum of cancer patients [8].	in plasma of cancer patients [9].	in the blood plasma of pancreatic cancer patients [10].	instability (MSI) and loss of heterozygosity (LOH) in cfDNA [11].	fetal DNA (cffDNA) in maternal plasma [12].	quantification of mutations in the plasma of patients with colorectal tumors [13].	ctDNA in the tumor [14 - 17].	of mutations from ctDNA by Thiery <i>et al.</i> [18].	used for oncology research [19].	alternative to invasive tissue biopsies [20].

Liquid biopsy aims at intimately observing the progress of cancer or treatment efficacy with minimal risk and burden for the patient and physician. The liquid biopsy may enable detailed profiling of tumor and early detection of a relapse with the isolation of CTCs and ctDNA (Fig. 1).



**Fig. (1).** An overview of blood-based liquid biopsy. In cancer patients, blood contains CTCs, ctDNA, exosomes. The liquid biopsy may enable detailed profiling of tumor and detection of a relapse relative early with the isolation of CTCs and ctDNA.

The analysis of ctDNA by different detection methods has an important role in the follow-up of patients, especially those diagnosed with cancer, and who have certain genetic markers. However, these methods have both advantages and disadvantages (Table 2).

**Table 2.** ctDNA detection methods.

Methods for Detection	Technique	%ctDNA	Application	Advantages	Limitations
Digital PCR [16, 21 - 24]	Droplet-based digital PCR Microfluidic digital PCR	~0.01%	Known point mutations	High sensitivity	Only can detect specific genetic loci and known mutations

## Pitavastatin and Cancer: Current and Future Prospects

Saeb Aliwaini<sup>1,\*</sup>

<sup>1</sup> Department of Biological Sciences and Biotechnology, Faculty of Sciences, Islamic University of Gaza, Rimal Street, Gaza 108, Palestine

**Abstract:** Pitavastatin is a synthetic 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitor, which was approved for the primary treatment of hypercholesterolemia and combined dyslipidemia since 2009. Today, *in vitro* and *in vivo* studies have shown pitavastatin as a potentially effective therapeutic agent for different cancers, including; liver, ovarian, breast, skin, and intestinal cancers. These studies have evaluated pitavastatin both as a single treatment and in combination with other therapeutic options. This chapter focuses on the potential anti-cancer effects of pitavastatin, including its mechanism of action as well as the potential adverse reactions linked to its clinical use.

**Keywords:** Anti-cancer, Anti-inflammatory, Apoptosis, Autophagy, Cell cycle arrest, Pitavastatin.

### INTRODUCTION

Cancer is one of the deadliest diseases and accounts for 13% of total deaths worldwide [1]. It is a multifactorial disease that is unlikely to be treated with a single treatment. Surgery is the primary strategy for treating many cancers. Other forms of cancer treatments include radiation therapy, hormone therapy and chemotherapy. Unfortunately, despite the enormous efforts invested to treat cancers, there has been limited success because of the undesired side effects and drug resistance induced by the aforementioned treatments. Most of the current cancer treatments have been shown to kill cancer cells by activating apoptotic cell death [1]. Apoptosis is mainly executed by two caspase-dependent pathways: the extrinsic pathway and the intrinsic pathway.

---


\* Corresponding author Saeb Aliwaini: Department of Biological Sciences and Biotechnology, Faculty of Sciences, Islamic University of Gaza, Rimal Street, Gaza 108, Palestine; Tel: +970 8 2644400; Fax: +970 8 2644800; E-mail: Saib.iwini@gmail.com

Both pathways depend on a group of signaling pathways that regulate the programmed cell death process. However, cancer cells usually develop several mutations or alterations to avoid apoptosis. While apoptosis has generally been considered as the principal mechanism of cell death induced by cancer treatments, it has become obvious that it can also induce autophagy. The later cellular process is a degradation mechanism involving the recycling of cellular organelles and macromolecules. Autophagy is usually activated under conditions of stress to promote cell survival. There is, however, a debate as to whether the activation of autophagy in response to chemotherapeutic agents enhances or inhibits cell death [2].

Statins, a group of drugs that reduce plasma cholesterol levels, have been shown to induce both apoptosis and autophagy [3]. They were initially developed as treatments for hypercholesterolemia and to manage coronary heart disease [4]. These drugs block the cholesterol biosynthesis pathway by inhibiting the rate-limiting enzyme in the mevalonate (MVA) pathway, 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) (Fig. 1).

Statins are categorized into two major classes: the natural products-based statins (mevastatin, lovastatin, pravastatin, simvastatin) and the synthetic statins (fluvastatin, atorvastatin, cerivastatin, pitavastatin, rosuvastatin) [4, 5]. Structurally, statins comprise of two parts: the pharmacophore moiety (either being carboxylic acid chain in the active form or a lactone ring in the prodrug) that is responsible for the inhibition of HMGCR, and the ring system moiety that is different for each type [4]. While most statins are administered orally as actively opened rings, lovastatin and simvastatin are administered as lactones that are activated in the body [4, 6]. However, statins differ in their pharmacological effects, lipophilicity, hydrophilicity, kinetic profile, rate of metabolism and the formation of active and inactive metabolites. Myotoxicity and rhabdomyolysis are the most severe undesired effects of statins [7, 8].

The anti-cancer properties of statins have been demonstrated in monotherapy and in combination therapy with other chemotherapeutics [9 - 11]. Different statins such as simvastatin, lovastatin, mevastatin, fluvastatin, and pitavastatin have been shown to induce apoptotic cell death in a subset of *in vitro* and *in vivo* cancer cell models [9, 12 - 16]. Recently, pitavastatin gained more attention for the prevention and treatment of cancer, as it can inhibit cell proliferation, inflammation, tumor initiation, and progression and inducing different modes of cell death [17 - 20].



**Fig. (1).** Schematic illustration of the mevalonate pathway and its implications on inflammation and cell proliferation. Sites of action of HMG-CoA reductase inhibitors (statins, e.g., pitavastatin) are indicated.

Pitavastatin has been shown to exert potent cytotoxic effects on glioblastoma growth *in vivo* [16]. The mechanism of action of pitavastatin includes up-regulation of the cell cycle regulator p21 and inhibition of NF- $\kappa$ B, which resulted in cell cycle arrest and apoptosis [21, 22]. Interestingly, autophagic cell death was also shown to be induced by pitavastatin [19]. Finally, recent findings showed that pitavastatin and dacarbazine synergistically inhibit melanoma cell survival by inducing cell cycle arrest, apoptosis, and autophagy [15].

The objectives of this chapter are: 1) review the available preclinical and clinical literature focused on the potential efficacy of pitavastatin drugs in cancer treatment, and 2) discuss the molecular mechanisms driving its anti-cancer effects. This chapter also offers insights into the possible future directions of pitavastatin.

### PITAVASTATIN: THE CHEMICAL COMPOUND

Pitavastatin, (+)-monocalcium bis (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoate] (M.W. 880.98) is a synthetic

## Cholesterol: A Potential Target for Intervention in Anti-Cancer Therapy

Nimai Chand Chandra<sup>1,\*</sup>, Amar Preet Kaur<sup>2,#</sup>, Ayantika Talukdar<sup>3,#</sup>, Nimisha Saxena<sup>4,#</sup> and Shrimanjunath Sankanagoudar<sup>5,#</sup>

<sup>1</sup> Department of Biochemistry, All India Institute of Medical Sciences, Phulwarisharif, Patna – 801507, Bihar, India

<sup>2</sup> Department of Biochemistry, All India Institute of Medical Sciences, Kunraghat, Gorakhpur – 273008, Uttar Pradesh, India

<sup>3</sup> Division of Genetics and Development, Krembil Research Institute, University Health Network, Toronto, ON, M5T 0S8, Canada

<sup>4</sup> Department of Biochemistry, KDMCH & Research Center, Akbarpur, Mathura-281406, Uttar Pradesh, India

<sup>5</sup> Department of Biochemistry, All India Institute of Medical Sciences, Basni, Jodhpur – 342005, Rajasthan, India

**Abstract:** Being polycyclic hydrocarbon, cholesterol has the quality for making DNA adduct within cell nucleus. Structurally cholesterol and its epoxide are very close to polycyclic carcinogenic precursor *e.g.* benzo-alpha-pyrene, which is well known for its carcinogenic pulse by forming adduct to chromosomal DNA. In fact normal cross membrane transports of cholesterol, either on cell surface or on nuclear membrane turn desynchronized in cancer tumor cells. A cholesterol loaded cell nucleus has been correlated to wobbly cell cycle operation and aberrant cell proliferation in many cancer type *viz.* leukemia, breast carcinoma, prostate carcinoma *etc.* A reprogrammed cholesterol metabolism affects tumor associated immune cell activity, cellular apoptosis and kinetics of cell survival. In fact, cholesterol concentration within cell nucleus has been found correlated with cellular life span. In tumor microenvironment intracellular cholesterol concentration varies from one to another cell type. While it increases within tumor cells, the surrounding immune cells die because of scarcity of intracellular cholesterol concentration. Intervention of this biphasic role of cholesterol in and around the cancer tumor could be a model target for anti-cancer therapeutic management.

\* Correspondence author **Nimai Chand Chandra:** Department of Biochemistry, All India Institute of Medical Sciences Patna, Phulwarisharif, Patna – 801507, Bihar, India: Tel: +919955901206; E-mail: nc1\_chandra@hotmail.com

# All co-authors have equal contribution in the preparation of this book chapter.

Atta-ur-Rahman (Ed.)

All rights reserved-© 2021 Bentham Science Publishers

**Keywords:** Anti-cancer therapy, Breast cancer, Carcinogenesis, Cholesterol homeostasis, Leukemia, Low density lipoprotein, Low density lipoprotein receptor, Metformin, Nuclear cholesterol, Peripheral type benzodiazepine receptor, PD-1, PD-L1, Polycyclic hydrocarbon, Prostate cancer, Statin.

## INTRODUCTION

In a recent report, it has been emphasized that atherosclerosis and carcinoma are two different episodes of dysfunctional cholesterol homeostasis [1]. While in one hand, cholesterol is a part of essential commodities used for maintaining cellular metabolism [2], membrane scaffolding [3, 4] and epi-chromosomal ventures [5]; on the other hand, cumulative accumulation of cholesterol, either in extra- or intra-cellular edge, is injurious to health. While an atherosclerotic association of cholesterol in cardiovascular diseases (CVD) and stroke is a well-known feature for a long time due to its excess deposition and adherence in the intima of blood vessels, an upcoming concurrence of message on over-accumulation of cholesterol in intracellular domain, either in the cytosol or cell nucleus, is now targeting the oncogenic affair of cholesterol in a biological system.

Intracellular cholesterol homeostasis is maintained from the balanced activity of three-way operations. These are 1) LDL receptor (LDLR) mediated influx of extracellular cholesterol, 2) Synthesis of cholesterol within cells by the activity of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) and 3) Efflux of cholesterol by ATP-binding cassette (ABC) transporter proteins such as ABCA1 and ABCG1 [6, 7]. Again, LDLR activity is regulated by various factors, *e.g.*, its inactive existence in a bound state with insulin receptor [8], feedback regulation by sterol regulatory element-binding proteins (SREBPs) [9], and post-transcriptional regulation by PCSK9 [10]. Genetic heterogeneity guides the potentiality of the major cholesterol routes [6, 7]. An imbalance of the equilibrium in these processes predates carcinogenesis [11, 12]. In various types of cancer, hyper-expressions of active LDLR and HMGCR have been documented [6, 13]. Cholesterol rich lipid rafts or microdomains [14, 15], especially on nuclear surface membrane, have been found to coordinate in organizing the signalling molecules and transduction of signals [16] for cell proliferation within tumor tissue.

The pivotal role of cholesterol, within membrane lipid microdomains of the cell nucleus, on transcription regulation to rule proliferation, differentiation and apoptosis with the alterations of the chromosomal lipid-protein complex has been recorded in several reports since the early decade of the 21<sup>st</sup> century. Recent works also have monitored the impact of LDL transmitted cholesterol through LDLR on protein expressions in cell cycle operation [17, 18] and cancer cell



progression [19 - 22]. The entry of cholesterol from the cytoplasm to the cell nucleus is expected through the peripheral-type benzodiazepine receptor (PBR) situated on the nuclear surface membrane [20 - 24].

Reprogrammed cholesterol metabolism, either by cell-intrinsic or cell-extrinsic signal, in the tumor microenvironment (TME) cumulatively generates a convenient home for aggressive tumorigenesis. Cholesterol or cholesterol-derived polycyclic metabolites play intense roles in cancer cell progression by suppressing anti-tumor immune responses [25 - 27]. In pre- and post-TME, the immune cells die, maybe because of their insufficiently low intracellular cholesterol level [25, 26]. PI3K/AKT (phosphatidylinositol 3-kinase/protein kinase B) signalling, a dynamic regulator of cell proliferation, growth, survival, migration and metabolism, can up-regulate genes in the cholesterol pathway and found hyperactive in carcinoma tumors [28]. *MYC*, a viral oncogene, can up-regulate the mevalonate pathway [29]. Repression of LXR $\alpha$  signalling by hyperexpression of oncogene c-Fos elevates the production of cholesterol and cholesterol-derived oxysterols and bile acids [30], which in turn increases inflammation and carcinogenesis. Tumor suppressor p53 upregulates the cholesterol-efflux transporter ABCA1 to prevent excess cholesterol accumulation within the cells, and suppression of the mevalonate pathway by statins appears to effectively retard tumorigenesis in p53 loss [31]. Thus activities of tumor suppressors are also correlated with the metabolome of cholesterol homeostasis. In TME, low-pH-responsive genes are also associated with cholesterol homeostasis and inversely correlated with patient survival [32].

Lastly, cholesterol homeostasis is riddled between the pathology of carcinoma and atherosclerosis. In this context, the pleiotropic effects of statins drugs are in major focus. While statins are the marvels for taking care of atherosclerotic diseases like heart attack and stroke by inhibiting intracellular cytosolic enzyme HMGCR [33], the therapeutic potential of statins in cancer treatment [12] is also challenging ground. Inhibition of isoprenoid synthesis by statins can suppress down the mevalonic acid pathway, and its mechanism of action beyond cholesterol reduction (pleiotropic effects) [34], *i.e.*, plaque stabilization and improvement of endothelial functions, anti-inflammatory and anti-oxidative effects have attracted interests for its use in cancer therapy. But the reports from different sets of clinical trials on statins with various cancer phenotypes are now flummoxed with the school of mixed thoughts. In fact, statins and other cancer drugs are mystified in their mechanism of action to discriminate atherosclerosis and carcinoma from the perspectives of intracellular cholesterol homeostasis. These issues will be discussed in more detail in the following sections.

## SUBJECT INDEX

### A

- Aberrant crypt foci (ACF) 143  
 ABL tyrosine kinase 107  
 Abrogate Immune Cells 174  
 Absorptive-mediated transcytosis (AMT) 61, 62  
 Acetate 18, 26  
     cinnamyl 18  
 Acid 12, 17, 21, 102, 136, 137, 138, 142, 146  
     docosanoic 12  
     folinic 102  
     mevalonic 138, 142, 146  
     oleic 14  
     palmitic 17, 21  
     zoledronic 136, 137, 138  
 Activity 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 21, 25, 57, 106, 135, 144, 158, 159, 165, 174, 178, 182  
     androgenic 106  
     antigenic 4  
     antiproliferative 4, 182  
     anti-tumoral 174  
     atopic 159  
     enzyme 165  
     pitavastatin anti-cancer 135  
     pitavastatin antitumor 144  
     proapoptotic 178  
     synergistic 57  
     tumorigenic 158  
 Adenomas 97  
     early-stage 97  
 Adenomatous polyposis coli 98  
 Alluaudia procera didiereaceae 16  
 Aloysia citriodora verbenaceae 5  
 Amphiphilic structure 63  
 Amplified refractory mutation system 85  
 Anaplastic lymphoma kinase (ALK) 92, 94, 95  
 Androgen receptor (AR) 103, 104, 105, 110  
 Anti-cancer properties 133, 135  
 Anticancer strategy 180  
 Anti-CTLA4 Therapy 53  
 Antigen 44, 54, 58, 99, 103, 143, 162, 174, 176, 177, 182, 184  
     anti-cytotoxic 177, 182, 184  
     carcinoembryonic 99  
     foreign 176  
     immunogenic 174  
     nuclear 143  
     pulsed cytomegalovirus 58  
     tumor-associated 44  
     tumor cell 162  
 Anti-GITR Monoclonal Antibody 48  
 Anti-inflammatory agent 137  
 Anti-lymphocyte apoptotic ligands 178  
 Anti-migration Effect 141  
 Anti-proliferative effect 135, 137  
     synergistic 137  
 Anti-tumor, suppressing 156  
 Antitumor effects 24, 50, 135, 140, 142, 144  
     of pitavastatin 135, 142  
 Apoptosis 3, 4, 5, 132, 133, 134, 135, 138, 139, 140, 142, 154, 158, 169, 178, 179, 181  
     abolished 138  
     cellular 154, 158  
     defective 169  
     inducing 144  
 Apoptotic 176, 178, 181, 185  
     activity, biphasic 178  
     signal 176  
 Aromatase inhibitors (AIs) 89, 90, 91  
 AR 105, 111  
     oncogenic pathways 111  
     targeted therapy 105  
 Ataxia telangiectasia mutated (ATM) 104, 105, 110  
 ATP-binding cassette (ABC) 155, 167, 172  
 Azoxymethane 143  
     induced colon cancer 143  
     initiated colonic premalignant lesions 143

**B**

Bevacizumab 58, 100  
    chemotherapy 100  
    monotherapy 58  
Bim pro-apoptotic protein 138  
Biopsy 82, 83, 84, 93, 97, 103, 108, 113  
    excisional 113  
    invasive tissue 84  
    solid 82, 83  
Blood 37, 38, 40, 41, 44, 50, 61, 65, 68, 69,  
    146  
    brain barrier (BBB) 37, 38, 40, 41, 44, 50,  
        61, 65, 68, 69  
    creatine phosphokinase 146  
Bone morphogenetic protein 172  
Brain 39, 53, 64  
    metastases 53  
    microenvironment 39  
    stereotactic radiation 67  
    tissues 64  
Brain tumor(s) 37, 38, 41, 55, 58, 61, 67, 68,  
    69  
    barrier 41  
    growth 67  
    aggressive 38  
    aggressive primary 37  
    malignant paediatric 58  
Breast 83, 178  
    tissues 178  
    tumors 83  
Breast cancer 2, 24, 41, 82, 86, 87, 88, 89, 90,  
    91, 110, 135, 136, 137, 139, 140, 141,  
    143, 170, 171, 178, 181  
    cells 24, 135, 136, 137, 139, 140, 141, 181  
    cell lines 137, 170  
    metastatic 90  
    primary 90  
    ranks 86  
    resistance protein 41  
    risk 171  
    tumor 178  
Breathing smoke 157

**C**

Cancer 49 54, 55, 57, 82, 83, 86, 98, 103, 106,  
    111, 132, 143, 156, 170, 171, 173, 177,  
    179, 181, 183  
    colon 98  
    gynecological 111  
    intestinal 132  
    liver 143  
    mammary 170  
    ovarian 111  
    pancreatic 83  
    solid 82, 86  
    stem cells (CSCs) 55, 173  
    therapy 156, 171, 177, 179, 181, 183  
    tissue 103  
    vaccination 54  
    vaccines 49, 57, 106  
Cancer cells 2, 4, 64, 113, 135, 136, 137 138,  
    139, 141, 143, 144, 145, 147, 158, 168,  
    170, 171, 173, 174, 178, 179, 180, 181,  
    182  
    brain 138, 143  
    colon 136  
    death 181  
    growth elevation 171  
    human 141, 144, 147  
    immunogenic 174  
    lines 4  
    liver 137, 139  
    malignant 2  
    migration 141  
    non-small cell lung 139  
    oral squamous 139  
    pancreatic 137, 139  
    proliferation 136, 138, 141, 174  
    property immunogenic 178  
    prostate 170  
Cancer treatment 37, 43, 60, 63, 105, 110,  
    132, 133, 134, 135, 156, 181  
    developing effective 110  
    prostate 105  
Cancer tumor(s) 105, 154, 157, 174, 178, 179,  
    184, 185

- growing 179
- tissue 184, 185
- Carcinogen 158, 161, 162, 165, 173, 174, 175, 176, 177, 178, 179
  - chemical 174
  - exogenous 165
  - extracellular 176
  - mitogenic 173
- Carcinogenesis 98, 104, 143, 144, 155, 156, 157, 158, 167, 171, 174, 175, 178
  - processes predates 155
  - stimulated 98
- Carcinoma 52, 92, 157, 158, 167, 170
  - adenosquamous 92
  - developing metastatic 167
  - hypercholesterolemia-induced 158
  - mammary 157
  - metastatic prostatic 170
  - metastatic urothelial 52
  - sarcomatoid 92
- Cell cycle 158, 161, 166, 170
  - processes 170
  - proteins 158, 161, 166
- Cell death 25, 43, 59, 132, 133, 134, 139, 140, 141, 142, 162, 166, 167, 170, 177, 178, 183
  - activating apoptotic 132
  - apoptotic 133
  - autophagic 134, 142
  - cholesterol-depletion-induced 170
  - immune 162, 177, 178, 183
  - manipulating immune 178
  - ovarian cancer 139
  - peripheral immune 178
  - programmed 140
  - therapy-mediated 59
- Cell penetrating peptides (CPP) 62
- Cell proliferation 133, 134, 140, 142, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 165, 166, 173, 175, 177, 185
  - aberrant 154
  - aggressive tumorigenic 162
  - giant mitogenic cancer 185
  - immune 175
  - inhibited 140, 142
  - instigate tumor 173
  - mammalian 165
- Cellular 44, 185
  - heterogenicity 44
  - metabolomics 185
  - morphology 44
- Cellular cholesterol 163, 180
  - total 163
- Central nervous system (CNS) 37, 38, 40
- Cerebral edema 50
- Cerebrospinal fluid 65
- Chemotherapy 1, 2, 37, 38, 43, 48, 51, 57, 58, 67, 85, 88, 99, 100, 111, 112
  - adjuvant 85, 88
  - anti-VEGF 100
  - brain-targeted 67
  - neoadjuvant 85
- Chimeric antigen receptors (CARs) 53, 54
- Cholesterol 155, 160, 162, 163, 170, 181, 183, 184
  - chromatin-associated 170
  - cytoplasmic 162, 163, 170
  - decreasing membrane 181
  - efflux protein 183, 184
  - ester transfer protein (CETP) 181
  - targeting 175
  - total cell 163
  - transmitted 155
  - transporting 160
- Cholesterol biosynthesis 133, 164, 165, 168, 172, 173, 175, 180, 182
  - inhibitors 164
  - manipulating intracellular 173
  - pathway 133, 164, 165, 172, 182
- Cholesterol concentration 154, 162, 163, 166, 168, 173, 175, 177
  - intracellular 154, 166, 168, 175
  - nuclear 173
- Cholesterol-derived 156, 158
  - metabolites 158
  - polycyclic metabolites 156
- Cholesterol homeostasis 155, 156, 159, 158, 159, 162, 167, 168, 169, 170, 171, 172, 173, 179, 180, 182, 183, 184
  - altered 162

and cell survival 183  
cellular 159, 167  
dysfunctional 155  
in breast carcinoma 170  
in leukemia 168  
in prostate carcinoma 169  
systemic 159  
Cholesterol synthesis 180  
  blockers and Rho-GTPase inhibitors 180  
  genes 180  
Chronic lymphocytic leukemia (CLL) 169,  
  178  
Colon cancer tumors 145  
Colonoscopy 97  
Colorectal cancer 2, 82, 96, 97, 99, 102, 108,  
  142, 143  
  diagnosis 97  
  metastatic 102  
Comprehensive genomic profiling (CGP) 96  
Convection enhanced delivery (CED) 64, 66  
Cyclin-dependent kinases 91, 164  
Cyclodextrin 180  
Cytokines 44, 48, 49, 50, 69, 169, 173, 175  
  immunogenic 175  
  immunosuppressive 44  
Cytomegalovirus 53  
Cytotoxic 1, 3, 4, 5, 21, 25, 37, 45, 51, 53, 55,  
  59, 93, 140, 174, 176, 181  
  activity 1, 3, 4, 25, 51  
  agents 25, 181  
  blocking 37  
  effects 4, 5, 55, 140  
  macrophages 174  
  T lymphocytes (CTLs) 45, 51, 53, 59, 174  
Cytotoxicity 9, 61, 140  
  off-target 61

**D**

Dendritic cells (DCs) 51, 54, 174  
Disease 2, 3, 83, 85, 86, 92, 96, 99, 105, 108,  
  109, 112, 113, 133, 139, 142, 155, 156  
  atherosclerotic 156  
  cardiovascular 142, 155

coronary heart 133  
heterogeneous 96, 109  
inflammatory 139  
metastatic 89, 108  
neurodegenerative 3, 139  
solid tumor cancer 113  
DNA 45, 65, 146, 157, 162, 164, 165  
  adduct formation 158  
  damage repair 65  
  duplication 162  
  repair 157  
  synthesis 146, 164, 165  
  vaccine 45  
DNA replication 41, 162, 163, 164  
  and cell proliferation 163  
Dyslipidemia 165

**E**

Effect of Carcinogen 175, 176  
  on B-cell Immunity 176  
  on T-Cell Immunity 175  
Effects 52, 68, 135, 137, 139, 141, 142, 145,  
  156, 158, 174, 181  
  anti-inflammatory 135, 141, 142  
  anti-migratory 135  
  anti-oxidative 156  
  anti-tumorigenic 174  
  apoptotic 139  
  carcinogenic 158, 174  
  cholesterol-depleting 181  
  cytostatic 137  
  immune 52  
  immunomodulating 145  
  reduced toxic 68  
Epithelial breast cells 136  
Epstein-Barr virus (EBV) 109

**F**

Fatigue 48, 53  
FDA for melanoma treatment 52  
Fibroblasts 51, 163, 173  
  human 163  
Flow cytometry 139

Food and drug administration (FDA) 43, 50, 52, 53, 57, 91, 92, 111  
Fulvestrant therapy 91  
Function 4, 41, 42, 57, 101, 102, 106, 110, 156, 162, 170, 171, 174, 175, 182  
cancer cell 170  
cytotoxic T cells 57  
endothelial 156  
immune 175  
motor 42  
peripheral immune cell 174

## G

Gastrointestinal 53, 96, 106, 107  
stromal tumors 106  
stromal tumors mutations pathway 107  
GATA binding protein 97  
Gene 106, 110, 112, 178  
expression 112, 178  
fusions 106  
methylation 110  
Genomic 2, 104, 105, 176  
hypermethylation 104, 105  
instability 2  
transcription 176  
Genotoxicity 157  
Glioblastoma 42, 134, 136, 140  
cell lines 136  
cells 140  
growth 134  
standard treatment 42  
Glioma cell lines 142  
Gliomas 38, 39, 40, 41, 51, 59  
circumscribed 39  
diagnosed high-grade 51  
Glucose transporters 62  
Granulocyte-macrophage colony-stimulating factor (GM-CSF) 51  
Growth 2, 3, 41, 51, 58, 96, 100, 143, 145, 156, 159, 166, 167, 168, 170, 175, 176, 178, 182, 183  
activating T-cells 58  
aggressive 178

cellular 159, 182  
factors 100, 175, 183  
inhibition, marked tumor 51  
metastatic 2  
non-cancerous 96  
tumorigenic 166

## H

Head and neck cancer 82, 108, 109  
squamous cell carcinoma 82, 108  
Head and neck squamous cell carcinoma (HNSCC) 109, 110  
Heat shock proteins (HSPs) 56  
based Vaccine 56  
Hepatic premalignant lesions 144  
Hepatocellular carcinoma 136  
High-density lipoprotein (HDL) 179, 180  
High-grade serous ovarian cancer (HGSO) 111, 112  
Hodgkin's lymphoma treatment 52  
Homeostasis 40, 142, 158, 167, 168, 174  
cellular 158  
intracellular 168  
processes 142  
Human 100, 109, 136, 137, 142, 168  
epithelial cancer 100  
leukemic cells 168  
liver and hepatocellular carcinoma 136  
monocytic tumor cells 137, 142  
pancreatic cells 137  
papilloma virus (HPV) 109  
Hypersensitivity reactions 146  
Hyperthermia 65

## I

Immune  
activity 176  
adjuvants 37, 59  
checkpoint inhibitors (ICIs) 37, 38, 49, 50, 51, 53, 56, 58  
reaction 53  
response, cell-mediated 49, 50

- Immune cell(s) 156, 162, 173, 174, 175, 176, 177, 178, 179, 182, 184, 185  
oriented 178  
suppression 173
- Immune system 68, 174, 175, 176  
adaptive 174  
innate 174
- Immune system 43, 54, 174  
cells 54  
programming 174  
responses 43
- Immunity 54, 56, 162, 168, 171  
antitumoral 54  
cell-mediated 162
- Immunization 54
- Immunogenicity 50, 58
- Immunomodulators 37, 69
- Immunostimulants 49  
agents 49
- Immunosuppression 37, 43, 50, 59, 174, 175  
inducing 174  
targeting 59  
tumor-mediated 37, 43
- Immunosuppressive solid tumor 44
- Immunotherapeutic pathways 59
- Immunotherapies for malignant glioblastoma 49
- Immunotherapy 2, 37, 38, 43, 44, 48, 49, 51, 53, 56, 58, 68, 69  
active 48, 49  
adoptive 53  
anticancer 48  
passive 48, 51  
targeted 51
- Infiltrative tumor cells 68
- Inhibitors 37, 38, 49, 51, 89, 90, 91, 94, 100, 103, 145, 164, 172, 182  
aromatase 89, 90, 91  
cyclin-dependent kinase 137  
immune checkpoint 37, 38, 49, 51  
tyrosine kinase 94, 100, 182
- Instability, microsatellite 52
- Intracellular cholesterol 155, 156, 159, 162, 163, 167, 168, 171, 173, 176, 179, 180, 183  
accumulation of 168, 171, 179  
deficiency 162  
deprivation 176  
homeostasis 155, 156, 159, 162, 167, 173, 179, 180, 183  
role of 163, 167, 176
- Involved Field RT (IFRT) 43
- ## J
- Joint expert committee on food additives (JECFA) 157
- ## K
- Karnofsky performance status (KPS) 38
- Key signalling pathways 179
- Kinase 48, 87, 100, 106, 145, 156, 183  
extracellular signal-regulated 145  
herpes simplex virus thymidine 48  
internal tyrosine 106  
receptor tyrosine 87, 100, 106, 183
- ## L
- Leukemia 98, 168  
acute myelogenous 98  
lymphocytic 168  
lymphoid 168  
myeloid 168
- Ligand binding domain (LBD) 110
- Liver X receptor (LXRs) 168, 171
- Low density lipoprotein (LDL) 63, 155, 159, 166, 168, 171, 173, 179, 180, 183
- Lung cancer 2, 91, 92, 96, 103, 109, 136, 143, 145  
cells 136, 143, 145  
metastatic 91  
small cell 92
- Lung tumor 157
- Lymphocytes 44, 50, 52, 54, 168, 169, 175, 178  
therapeutic autologous 44  
tumor-infiltrating 44

Lymphokine-activated killer cells 50

## M

Macropinocytosis 141

Malignancy 100, 112, 179

Malignant 2, 38, 44, 49, 56, 57

cell growth 2

glioblastoma 44, 49

glioma site 57

neoplasms 2

transformation 56

tumors, primary 38

Melanoma 50, 52, 53, 98

cutaneous 98

malignant 53

metastatic 50

treatment 52

Membrane transports 154

Memory, long-term immune 38, 68

Metabolome, cellular 184

Metastasis 2, 83, 89, 99, 100, 106, 141, 170,

173, 174, 178, 179

bone 106

cancer cell 141

process 83

Metastatic 88, 89, 90, 91

breast cancer (MBC) 88, 89, 90, 91

environment 89

Metastatic NSCLC 94

untreated 94

Metastatic prostate adenocarcinoma 110

hormone-naive 110

Metformin 155, 182, 183

anti-diabetic agent 182

Methylguanine-DNA methyltransferase 52

Microautophagy 139

Microdomains 155, 179

membrane lipid 155

stable membrane structure 179

Micropinocytosis 141

and cancer cell migration 141

Mitogen-activated protein kinases (MAPK) 5,  
98, 100, 183

Mitogenic stimulation 168

Molecular residue disease (MRD) 88

Monoclonal antibodies 37, 49, 55, 59, 100,  
102

anti-angiogenic 59

anti-EGFR 55

anti-epidermal growth factor receptor 102

Monomeric glycoprotein 51

Monoterpene glycoside 24

Mutant allele frequency (MAF) 99, 100

Mutations 44, 57, 84, 85, 87, 89, 90, 93, 94,  
98, 99, 100, 105, 106, 108, 110, 112

cancer suppression 110

genetic 44, 100

Myeloid-derived suppressor cells (MDSCs)  
44, 57

## N

Nano-drug delivery systems 60

Nanomedicines 38, 60, 61, 62, 63, 68

liposomes-based 63

strategies 68

Nanometric dimensions 64

National comprehensive cancer network  
(NCCN) 94

Natural killer cells 174

Neck cancer 52, 82, 108, 109

squamous cell carcinoma 108

Neo-adjuvant chemotherapy (NAC) 88

Neoplastic 106, 183

transformation 106

tumor cells 183

Neural stem cells (NSCs) 50

Next-generation sequencing (NGS) 85, 87,  
114

Non-small cell lung cancer (NSCLC) 82, 91,  
92, 93, 94, 95, 139

NSCLC morphology 92

Nuclear 4, 142, 146, 162, 169, 179

chromosomes 169

factor kappa-light-chain-enhancer 4

membrane microdomains 162, 179

surface proteins 162




- translocation 142, 146  
Nucleoplasm 162
- O**
- Oils 1, 3, 4, 25, 157  
concentrated aromatic 3  
fragrant 3  
lotus 3  
lubricating 157  
motor 157  
Oligonucleotides 64  
Oncogenesis 179  
Oncology 44, 92  
thoracic 92  
Oncolytic herpes simplex virus 59  
Oral 42, 109, 136, 137  
carcinomas 137  
cavity cancer 109  
cytotoxic DNA-alkylating agent 42  
squamous cell carcinoma cells 136  
Organogenesis 163  
Organ regeneration 163  
*Origanum dictamnus* 12  
Osteolytic lesions 145  
Ovarian cancer (OC) 111, 112, 136, 137, 138, 139, 140, 143, 144  
cells 136, 137, 138, 140, 143
- P**
- Pancreatic adenocarcinoma 136, 143  
Pathologies, carcinogenic 166  
Pathways 4, 38, 56, 111, 132, 133, 139, 140, 145, 146, 164, 156, 158, 165, 168, 169, 172, 181  
anabolic 175  
caspase-dependent 132  
cholesterol biosynthetic 172  
cholesterol synthesis 164  
immunological 59  
intrinsic apoptotic 169  
mevalonic acid 156  
mitochondria-mediated 139  
oncogenic Hedgehog 158  
programmed cell death 140  
sterol biosynthesis 181  
Peptide vaccine 55  
Plasma 84, 88, 90, 96, 97, 98, 102, 108, 109, 159, 168  
cholesterol 168  
ctDNA analysis 88  
ctDNA levels 88  
healthy control 97  
maternal 84  
membrane transporter 159  
mutations 109  
Plasmid encoding 58  
Polycyclic 157, 159, 177  
carcinogenic 159  
Polycyclic 154, 155, 157, 174, 177, 183  
aromatic hydrocarbons (PAHs) 157, 174, 183  
carcinogenic precursor 154  
cholesterol 157  
hydrocarbons 154, 155, 157, 177  
Polyethylene glycol 63, 65  
Post 41, 181  
mitotic state, definite 41  
transcriptional modifiers 181  
Precancerous lesions 97  
Progesterone receptor (PR) 86, 182  
Prognosis 38, 91, 104, 112  
aggressive 112  
influence GBM 38  
long-term 104  
of prostate cancer 104  
optimal 91  
Prognostication 112  
Prognostic Biomarker 88, 92, 99, 04  
in colorectal cancer 99  
in prostate cancer 104  
of breast cancer 88  
Programmed cell death protein 183  
Progression 45, 46, 48, 51, 59, 67, 68, 87, 90, 91, 93, 94, 99, 100, 105, 112, 133, 156, 158, 176  
cancer cell 156, 158  
carcinogens instigate tumor cell 176

- free survival (PFS) 45, 46, 48, 51, 59, 67, 90, 91, 93, 94, 112
  - Progressive 2, 169
    - CLL profile 169
    - transformation 2
  - Pro-inflammatory cytokines 141, 144
    - reducing 144
  - Prostate 2, 26, 103, 170, 178
    - carcinogenic 178
  - Prostate cancer 103, 104, 105, 111, 155, 167, 169, 170, 178
    - advanced lethal 103
    - castration-resistant neuroendocrine 104
    - lethal 111
    - metastatic castration-resistant 103
    - regressions, complete 111
    - tissue 170
  - Prostate-specific antigen (PSA) 103, 104, 105
  - Proteins 4, 56, 59, 61, 64, 82, 97, 106, 110, 137, 138, 139, 140, 144, 147, 159, 163, 164, 172, 178, 181
    - autophagy-related 140
    - cell lymphoma 4
    - cyclin 164
    - decreasing cholesterol ester transfer 181
    - inhibitory apoptotic 138
    - intracellular 106
    - intracellular antiapoptotic 56
    - lipid transfer 163
    - novel peptide-Fc fusion 59
    - regulatory element binding 172
    - retinoblastoma 110
- Q**
- Quantum dots (QDs) 65
- R**
- Radiation 55, 58, 66, 136
    - stereotactic 66
  - Radiation therapy 2, 37, 38, 48, 52, 68, 132
    - hypofractionated 48, 52
  - Radiological imaging techniques 92
  - Radiotherapy treatment 88
  - Rapamycin 4, 67
    - albumin-bound 67
  - Ras 87, 101, 102, 145, 147
    - inhibited 145
    - neuroblastoma 87
  - RAS 98, 100, 106, 145
    - genes 98
    - mutation status 100
    - pathways 100, 106
    - proteins 145
    - RAF-MEK-ERK signaling pathway 100
  - Reactive 4, 172
    - nitrogen species (RNS) 4
    - oxygen species (ROS) 4, 172
  - Regulatory protein 159, 160, 172
    - acute 159, 160
  - Resistance 42, 55, 56, 82, 89, 90, 92, 94, 95, 100, 101, 102, 108, 111, 171
    - endocrine therapy 90
    - mutations 82, 92, 108
    - phenomena 56
  - Rhabdomyolysis 133
  - Rho-GTPase inhibitors 180
  - Risedronate 136, 137, 138
  - Risk 83, 86, 175
  - RNAase degradation 63
  - Role, immunosuppressive 57
  - ROS proto-oncogene 87
  - RT-induced leukoencephalopathy 43
- S**
- Sarcoma 87, 92
    - v-raf murine 87
  - Schinus terebinthifolius* 4, 9
  - Skin sarcomas 157
  - Small cell lung cancer (SCLC) 82, 91, 92, 94, 139
  - Solid-lipid nanoparticles (SLNs) 64
  - Solid tumors 44, 85, 87
    - advanced 44
    - primary 87
    - resected 85

- Squamous cell carcinoma (SCC) 82, 92, 109  
Stem cells 50, 55, 140, 145  
    human colon carcinoma 145  
    malignant cancer 55  
    neural 50  
Steroid 160, 167, 179, 183  
    hormones 167, 179  
    regulatory element binding protein 173, 183  
    synthesizing cells 160  
Steroidogenesis 170, 180  
Sterol 155, 165, 171, 172, 181, 183  
    biosynthesis 181  
    regulatory element-binding proteins (SREBPs) 155, 171, 172, 183  
    synthesis 165  
Stress 2, 3, 41, 133, 140, 143, 146  
    environmental 2  
    genotoxic 41  
    modulating endoplasmic reticulum 146  
    oxidative 143  
Stroke 155, 156  
Surgical 37, 38, 43, 47, 88, 185  
    debulking 37  
    interventions 43, 88, 185  
    procedure 47  
    techniques 38  
Survival 38, 42, 43, 44, 48, 51, 52, 55, 56, 64, 65, 88, 89, 90, 94, 105, 112, 145, 167, 168, 169  
    disease-free 88  
    months overall 89  
    progression-free 48, 90, 94, 112  
    prolonged 38  
Synthesis 159, 160, 161, 179, 180, 181, 182  
    epoxide 159  
    fatty acid 182  
    inhibiting lipid 180  
    isoprenoid 156, 181  
    membrane 175, 182  
    steroid 159, 160, 161  
Synthetic 55, 63  
    CSCs-associated peptides 55  
    polymers 63  
Systems 4, 96  
    biliary 96  
    nanostructure 4
- T**
- Targeted therapy 89, 94  
    of breast cancer 89  
    of non-small cell lung cancer 94  
Therapeutics 37, 41, 68  
    anticancer 41  
    developing 37  
Therapies 2, 25, 38, 44, 48, 49, 50, 54, 58, 60, 68, 82, 86, 88, 90, 103, 104, 106, 111, 132, 140, 180  
    adaptive cellular 49  
    adjuvant 44, 88, 111  
    androgen-deprivation 106  
    anti-cancer 140  
    antiEGFR 103  
    cell-generating 58  
    cholesterol-modulating anticancer 180  
    endocrine-based 90  
    hormone 2, 104, 132  
    immunomodulator 48, 49  
    immunostimulant 50  
    neoadjuvant 111  
    photodynamic 38  
Thrombocytopenia 48  
Tissue 2, 60, 61, 88, 94, 96, 97, 102, 103, 113, 141, 160, 168, 175, 179  
    benign prostate 103  
    cancerous 103  
    damaged 88  
    healthy 61  
    steroidogenic 160  
    targeted 60  
Tissue biopsy 83, 85, 86, 95, 96, 97, 103, 109, 113  
    simultaneous 95  
Toxicity 25, 43, 50, 57, 147, 177  
    consequent CNS 50  
    increased autoimmune 57  
    neurocognitive 43  
Transcriptional antagonism 142

- Transcription factor 146, 165  
  c-Fos, suppressing 146
- Transcription regulation 155
- Transcytosis 61, 62  
  absorptive-mediated 61, 62  
  mediated 62  
  transporter-mediated 61
- Transmembrane 51, 103  
  glycoprotein 51  
  protease 103
- Transport 40, 109, 160, 161, 163  
  energy-independent 163
- Transporter-mediated transcytosis (TMT) 61
- Treatment 42, 52, 54, 87, 93, 95, 96, 110  
  crizotinib 95, 96  
  docetaxel 93  
  enzalutamide 110  
  immune checkpoint inhibitor 52  
  immunotherapeutic 68  
  individualized 87  
  lymphoma 54  
  maintenance 42, 52
- Triple 102, 182  
  chemotherapy 102  
  negative breast cancer (TNBC) 182
- Tryptophan depletion 58
- Tumor-associated 44, 49, 53, 54, 57, 174  
  antigens (TAAs) 44, 49, 53, 54  
  macrophages (TAMs) 57, 174
- Tumor biology 92, 104  
  aggressive 92
- Tumor cell(s) 43, 83, 111, 113, 144, 158, 159,  
  161, 162, 173, 174, 176, 177, 178, 183,  
  185  
  growth 159  
  proliferation 144, 158, 161, 173, 177
- Tumor growth 59, 64, 99, 144, 145, 167, 173,  
  176, 180, 182  
  delayed subcutaneous 144  
  promotion 173  
  reduced 59, 64
- Tumor heterogeneity 82, 86, 92  
  detecting 82, 86
- Tumorigenesis 156, 167  
  aggressive 156
- Tumor suppressors 38, 141, 156, 168  
  mutated 141
- Tumor tissue 86, 98, 105, 108, 110, 112, 113,  
  155, 158, 167, 173, 179  
  analysis 105  
  cells 158, 173
- Tumor(s) 2, 3, 37, 38, 43, 44, 48, 53, 61, 82, 83,  
  84, 87, 100, 104, 106, 113, 141, 145, 168,  
  173, 174, 175, 176, 178, 179  
  developing 176  
  heterogeneous 83, 113  
  mammary 145  
  infiltrating lymphocytes (TILs) 44, 53  
  metastatic 82  
  non-lymphocytic 179  
  necrosis 141  
  pathogenesis 168  
  protein 87  
  treating fields (TTF) 43, 48
- Turcot syndrome 38
- Turmerone 14
- Tyrosine kinase inhibitors (TKIs) 93, 94, 95,  
  100, 107, 108, 182
- ## V
- Vaccination therapy 37, 69
- Vaccine 37, 38, 48, 55, 58, 59  
  anticancer 48  
  immunotherapeutic 55  
  tumor-associated peptides 59
- Vascular 50, 99  
  endothelial growth factor receptor (VEGFR)  
    99  
  leak syndrome 50
- ## W
- Whole-genome sequencing 85
- Women, postmenopausal 91
- World health organization (WHO) 39, 157
- ## Z
- Zingiber officinale* 11



---

## **PROF. DR. ATTA-UR-RAHMAN, FRS**

Prof. Atta-ur-Rahman, Ph.D. in Organic Chemistry from Cambridge University (1968) has 1,232 international publications (45 international patents and 341 books). He received the following awards: Fellow Royal Society (FRS) London (2006), UNESCO Science Prize (1999), Honorary Life Fellow Kings College, Cambridge University (2007), Academician (Foreign Member) Chinese Academy of Sciences (2015), Highest Civil Award for Foreigners of China (Friendship Award, 2014), High Civil Award Austria ("Grosse Goldene Ehrenzeischen am Bande") (2007), Foreign Fellow Chinese Chemical Society (2013), Sc.D. Cambridge University (UK) (1987), TWAS (Italy) Prize (2009). He was the President of Network of Academies of Sciences of Islamic Countries (NASIC), Vice President TWAS (Italy), Foreign Fellow Korean Academy of Science & Technology, President Pakistan Academy of Sciences (2003-2006) and (2011 – 2014). He was the Federal Minister for Science and Technology of Pakistan (2000 – 2002), Federal Minister of Education (2002) and Chairman Higher Education Commission/Federal Minister (2002-2008), Coordinator General of COMSTECH (OIC Ministerial Committee) (1996-2012), and the Editor-in-Chief of Current Medicinal Chemistry.